Bernard Leman, MD
Gastroenterology · Clive, IANPI 1972560597
Payments from drug & device makers
Across 798 payments — averaging $367.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$161K
- AbbVie$65K
- UCB Biosciences Inc.$19K
- Bristol Myers Squibb$19K
- Eli Lilly$18K
- Genentech, Inc.$4K
- plus $8K from 30 others
Across 5 payments — averaging $657.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 120 | $160,560 |
| AbbVie(2 entities) | 260 | $64,698 |
| UCB Biosciences Inc. | 3 | $19,410 |
| Bristol Myers Squibb | 58 | $18,693 |
| Eli Lilly | 6 | $18,495 |
| Genentech, Inc. | 2 | $4,000 |
| Johnson & Johnson(2 entities) | 103 | $1,718 |
| Roche Products Limited | 1 | $1,000 |
| Pfizer | 58 | $630 |
| Phathom Pharmaceuticals, Inc. | 11 | $368 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $355 |
| Ironwood Pharmaceuticals, Inc | 20 | $344 |
| Lilly USA, LLC | 15 | $329 |
| UCB, Inc. | 12 | $325 |
| Merck | 17 | $310 |
| Sanofi | 11 | $293 |
| E.r. Squibb & Sons, L.L.C. | 3 | $279 |
| Regeneron Healthcare Solutions, Inc. | 7 | $224 |
| Ardelyx, Inc. | 13 | $207 |
| Gilead | 8 | $165 |
| Ipsen Biopharmaceuticals, Inc | 5 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Amgen | 7 | $117 |
| Organon | 9 | $114 |
| Braintree Laboratories, Inc. | 6 | $95 |
| Lumendi LLC | 1 | $93 |
| Apollo Endosurgery US Inc | 1 | $83 |
| Celltrion USA Inc. | 5 | $76 |
| Intercept Pharmaceuticals, Inc. | 5 | $68 |
| Novo Nordisk | 2 | $54 |
| Boehringer Ingelheim | 2 | $50 |
| QOL Medical, LLC | 3 | $48 |
| Boston Scientific | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
How this compares
$293,544 in reported general payments places this provider in the 95th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Clive
- Rajalakshmi IyerClive$1.1M
- Nagendra MyneniClive$66K
- Archana VermaClive$6K
- Christopher MulderClive$6K
- Benjamin PottebaumClive$6K
- Amol AgarwalClive$6K
- Ravi VemulapalliClive$5K
- Tercio LopesClive$5K
- Thomas MartinClive$2K
- Jeffrey BrannenClive$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.